Clinical Study

A Phase III Clinical Trial Evaluating Dcvax?-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multifor

Posted Date: May 15, 2019

  • Investigator: Rekha Chaudhary
  • Specialties:
  • Type of Study: Drug

This study will determine whether DCVax-Brain can slow growth and recurrence of brain tumors and whether it can extend overall survival. Participating patients will be treated with the study drug or placebo. Treatment can last up to 36 months. Patients will be followed-up for the rest of their lives

Criteria:

Eligible Patients Must Have A Brain Tumor

Keywords:

20221, Brain Cancer, Brain Tumor, Gbm, Glioblastoma Multifo

For More Information:

Uc Cancer Institute
513-584-7698
kastla@ucmail.uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.